- Home
- AEHL vs QLGN Comparison
AEHL vs QLGN Comparison
Compare AEHL & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEHL
- QLGN
- Stock Information
- Founded
- AEHL 1993
- QLGN 1996
- Country
- AEHL United States
- QLGN United States
- Employees
- AEHL N/A
- QLGN N/A
- Industry
- AEHL Building Materials
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- AEHL Industrials
- QLGN Health Care
- Exchange
- AEHL Nasdaq
- QLGN Nasdaq
- Market Cap
- AEHL 4.0M
- QLGN 3.4M
- IPO Year
- AEHL 2007
- QLGN N/A
- Fundamental
- Price
- AEHL $0.18
- QLGN $4.18
- Analyst Decision
- AEHL
- QLGN
- Analyst Count
- AEHL 0
- QLGN 0
- Target Price
- AEHL N/A
- QLGN N/A
- AVG Volume (30 Days)
- AEHL 1.6M
- QLGN 54.9K
- Earning Date
- AEHL 09-30-2024
- QLGN 11-14-2024
- Dividend Yield
- AEHL N/A
- QLGN N/A
- EPS Growth
- AEHL N/A
- QLGN N/A
- EPS
- AEHL N/A
- QLGN N/A
- Revenue
- AEHL $69,082,235.00
- QLGN N/A
- Revenue This Year
- AEHL N/A
- QLGN N/A
- Revenue Next Year
- AEHL N/A
- QLGN N/A
- P/E Ratio
- AEHL N/A
- QLGN N/A
- Revenue Growth
- AEHL 1.87
- QLGN N/A
- 52 Week Low
- AEHL $0.16
- QLGN $3.34
- 52 Week High
- AEHL $6.41
- QLGN $30.50
- Technical
- Relative Strength Index (RSI)
- AEHL 35.04
- QLGN 43.01
- Support Level
- AEHL $0.16
- QLGN $3.53
- Resistance Level
- AEHL $0.23
- QLGN $4.39
- Average True Range (ATR)
- AEHL 0.04
- QLGN 0.33
- MACD
- AEHL 0.01
- QLGN 0.06
- Stochastic Oscillator
- AEHL 17.69
- QLGN 50.98
About AEHL Antelope Enterprise Holdings Limited
Antelope Enterprise Holdings Ltd is a manufacturer of ceramic tiles in China. Its ceramic tiles are used for exterior siding, interior flooring, and design in residential and commercial buildings. The company's products are Porcelain, Glazed, Glazed porcelain, Rustic, and polished glazed tiles. The Company operates in the manufacturing and sale of medium to high-end ceramic tiles and providing business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.